Full Breakdown
Rising Drug Resistance and Undiagnosed Tuberculosis Cases in Europe
3/24/2026, 8:28:06 PM
Overview of the Tuberculosis Crisis
A recent report from the World Health Organization (WHO) and the European Centre for Disease Prevention and Control (ECDC) highlights a significant public health challenge in Europe: one in five tuberculosis (TB) cases remains undiagnosed. Despite a decline in overall TB cases, the region faces rising drug resistance, complicating efforts to eliminate the disease. TB continues to be the leading cause of death from a single infectious agent globally, with symptoms including persistent cough, fever, night sweats, and weight loss.
Current Statistics and Trends
The WHO European Region, which includes 53 countries in Europe and Central Asia, has seen a 39 percent reduction in TB incidence since 2015 and a 49 percent decrease in deaths. However, these reductions fall short of the WHO’s End TB Strategy targets for 2025, which aim for a 50 percent reduction in incidence and a 75 percent reduction in deaths. In the European Union, TB cases decreased by 33 percent, and deaths by 17 percent, insufficient to meet the 2030 goals. In 2024, over 160,000 new TB cases were reported, while the estimated actual cases were around 204,000, indicating that only 79 percent of new and relapse cases were notified.
The Challenge of Drug Resistance
The report emphasizes the growing challenge of drug-resistant TB, with multi-drug resistant cases among new patients at 23 percent and 51 percent among previously treated patients. These figures significantly exceed the global averages of 3.2 percent and 16 percent, respectively. The high rates of drug resistance reflect ongoing transmission and complicate treatment efforts, as antibiotic-resistant variants require longer treatment regimens with lower success rates.
Criticism and Calls for Action
Experts have raised concerns about the implications of undiagnosed cases and drug resistance. Hans Kluge, WHO Regional Director for Europe, noted that undiagnosed cases represent a failure in detection and a missed opportunity for early treatment, which could prevent further transmission. Ralf Otto-Knapp from the German Central Committee against Tuberculosis emphasized the need for stronger treatment and prevention services, particularly in low-incidence countries where TB predominantly affects vulnerable populations such as migrants, prison inmates, and individuals with HIV.
Official Statements and Responses
The WHO and ECDC report calls for increased investment in rapid diagnosis and treatment strategies to improve outcomes and meet public health targets. Kluge stated, “By investing in rapid diagnosis, shorter all-oral treatment regimens and stronger follow-up, countries can reach more people earlier.” Otto-Knapp echoed this sentiment, urging for enhanced access to new medicines and cross-border cooperation to combat the rising threat of multidrug-resistant tuberculosis.
Conclusion
The report underscores the urgent need for comprehensive strategies to address the dual challenges of undiagnosed tuberculosis cases and rising drug resistance in Europe. Without significant improvements in detection and treatment, the region risks falling further behind in its fight against this infectious disease.
